Do all patients with cancer thrombosis have the same risk of bleeding and recurrence? Particularities of lung cancer

References

• Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–464. doi: 10.1001/archinte.166.4.458
   PubMed Web of Science ®Google Scholar
• Horsted F, West J, Grainge MJ, et al. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLOS Med. 2012;9(7):e1001275. doi: 10.1371/journal.pmed.1001275
   PubMed Web of Science ®Google Scholar
• Bertoletti L, Madridano O, Jiménez D, et al. Cancer-Associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020. JACC Cardio Oncol. 2023;5(6):758–772. doi: 10.1016/j.jaccao.2023.09.003
   PubMedGoogle Scholar
• Eckardt JL, Wanek MR, Udeh CI, et al. Evaluation of prophylactic antibiotic use for delayed sternal closure after cardiothoracic operation. Ann Thorac Surg. 2018;105(5):1365–1369. doi: 10.1016/j.athoracsur.2017.12.012
   PubMed Web of Science ®Google Scholar
• Shargall Y, Schneider L, Linkins LA, et al. Double blind pilot randomized trial comparing extended anticoagulation to placebo following major lung resection for cancer. Semin Thorac Cardiovasc Surg. 2021;33(4):1123–1134. doi: 10.1053/j.semtcvs.2021.02.032
   PubMedGoogle Scholar
• Poenou G, Dumitru Dumitru T, Lafaie L, et al. Pulmonary embolism in the cancer associated thrombosis landscape. J Clin Med. 2022 sep 25;11(19):5650.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10),3484–3488. doi: 10.1182/blood-2002-01-0108
   PubMed Web of Science ®Google Scholar
• Mahé I, Chidiac J, Bertoletti L, et al. The clinical course of venous thromboembolism may differ according to cancer site. Am J Med 2017;130(3),337–347. doi: 10.1016/j.amjmed.2016.10.017
   PubMed Web of Science ®Google Scholar
• Bertoletti L, Gusto G, Quignot N, et al. Low molecular weight heparin treatment patterns and outcomes in cancer patients with acute venous thromboembolism: a nationwide cohort study in France. Cancers (Basel). 2023;15(11):3011. doi: 10.3390/cancers15113011
   PubMed Web of Science ®Google Scholar
• Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 2014;134(6),1214–1219. doi: 10.1016/j.thromres.2014.09.039
   PubMed Web of Science ®Google Scholar
• Laporte S, Bertoletti L, Romera A, et al. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients. Thromb Res 2012;130(6),853–858. doi: 10.1016/j.thromres.2012.08.290
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 3821599–1607 (2020). 17 10.1056/NEJMoa1915103
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 378615–624 (2017). 7 10.1056/NEJMoa1711948
   PubMed Web of Science ®Google Scholar
• Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3),781–790. doi: 10.1016/j.chest.2021.09.037
   PubMed Web of Science ®Google Scholar
• Agnelli G, Muñoz A, Franco L, et al. Apixaban and Dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost. 2022;122(5):796–807. doi: 10.1055/s-0041-1735194
   PubMedGoogle Scholar
• Mulder FI, van Es N, Kraaijpoel N, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE cancer study. Thromb Res. 2020;185, 13–19. doi: 10.1016/j.thromres.2019.11.007
   PubMed Web of Science ®Google Scholar
• Petit B, Soudet S, Poenou G, et al. Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible for a direct oral anticoagulant randomized controlled trial? Respir Med Res. 2023;85101069. doi: 10.1016/j.resmer.2023.101069
   PubMedGoogle Scholar
• Lafaie L, Hodin S, Saïb S, et al. Tyrosine kinase inhibitors and direct oral anticoagulants: in vitro evaluation of drug–drug interaction mediated by P‐glycoprotein. Fundam Clin Pharmacol. 2022;36(5):860–868.
   PubMed Web of Science ®Google Scholar
• Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, et al. Treatment algorithm in cancer-associated thrombosis: updated Canadian expert consensus. Curr Oncol. 2021;28(6):5434–5451. doi: 10.3390/curroncol28060453
   PubMed Web of Science ®Google Scholar